Activated macrophages release microvesicles containing polarized M1 or M2 mRNAs. Issue 5 (30th December 2013)

• Record Type: Journal Article
• Authors: Garzetti, Livia; Menon, Ramesh; Finardi, Annamaria; Bergami, Alessandra; Sica, Antonio; Martino, Gianvito; Comi, Giancarlo; Verderio, Claudia; Farina, Cinthia; Furlan, Roberto
• Is Part Of: Journal of leukocyte biology. Volume 95:Issue 5(2014)
• Page Start: 817
• Page End: 825
• Publication Date: 2013-12-30
• Subjects: cytokines -- inflammation; Leucocytes -- Periodicals; Reticulo-endothelial system -- Periodicals; 571.96
• DOI: 10.1189/jlb.0913485
• Languages: English
• ISSNs: 0741-5400

Abstract

Abstract : Microvesicles released by activated macrophages, and detected in biological fluids, may constitute a valuable biomarker to identify myeloid cell activation phenotype during disease. ABSTRACT: MVs are known vehicles of horizontal communication among cells, currently under scrutiny as powerful biomarkers in several pathological processes. The potential advantage of MVs relies on the assumption that their content reflects processes ongoing in pathologically relevant cell types. We have described that MVs of myeloid origin in the CSF are a marker of microglia/macrophage activation. Myeloid cells have different activation types, resulting in diverse functional phenotypes. Knowledge on the activation type of myeloid cells during disease would be of paramount importance for the understanding of ongoing pathogenic processes. We show here that macrophages activated in vitro in different ways all release increased amounts of MVs compared with NS cells. Moreover, we show that macrophage-derived MVs contain a repertoire of mRNAs that is not the result of casual sampling from the parental cells, as it is characterized by distinct mRNA enrichments and species. Nevertheless, mRNA content of MVs clearly allows identification in vivo of the activated phenotype of the cell of origin, indicating carryover of functional macrophage traits. We propose that detection of mRNAs in myeloid MVs permits identification of myeloid cell activation type during disease, allowing for further stratification of pathological processes.